Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 72, Issue 3, 2016, Pages 304-309

  Fogel, Jessica M ^a   Hudelson, Sarah E ^a   Ou, San San ^b   Hart, Stephen ^c   Wallis, Carole ^d   Morgado, Mariza G ^e   Saravanan, Shanmugam ^f   Tripathy, Srikanth ^g   Hovind, Laura ^c   Piwowar Manning, Estelle ^a   Sabin, Devin ^a   McCauley, Marybeth ^h   Gamble, Theresa ^h   Zhang, Xinyi C ^b   Eron, Joseph J ⁱ   Gallant, Joel E ^j   Kumwenda, Johnstone ^k   Makhema, Joseph ^l   Kumarasamy, Nagalingeswaran ^m   Chariyalertsak, Suwat ⁿ   Hakim, James ^o   Badal Faesen, Sharlaa ^p   Akelo, Victor ^q   Hosseinipour, Mina C ^i,k   Santos, Breno R ^r   Godbole, Sheela V ^s   Pilotto, Jose H ^t   Grinsztejn, Beatriz ^u   Panchia, Ravindre ^v   Mayer, Kenneth H ^w,x   Chen, Ying Q ^b   Cohen, Myron S ⁱ   Eshleman, Susan H ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d LANCET LABORATORIES   (South Africa)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^g NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^h FAMILY HEALTH INTERNATIONAL   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j Southwest CARE Center   (United States)

^k UNIVERSITY OF MALAWI   (Malawi)

^l BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^m VHS Medical Centre India   (India)

ⁿ CHIANG MAI UNIVERSITY   (Thailand)

^o UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^p UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^q KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^r HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^s NATIONAL AIDS RESEARCH INSTITUTE   (India)

^t HOSPITAL GERAL DE FORTALEZA   (Brazil)

^u Funda??o Oswaldo Cruz   (Brazil)

^v UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^w FENWAY INSTITUTE   (United States)

^x HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

ART failure; early ART; HIV; HPTN 052; resistance

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG TREATMENT FAILURE; EDUCATIONAL STATUS; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; OBSERVATIONAL STUDIES AS TOPIC; TREATMENT FAILURE; VIRAL LOAD;

EID: 84976315930     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000951     Document Type: Article

References (23)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
2. Cohen MS, Chen YQ, McCauley M, et al. Final results of the HPTN 052 randomized controlled trial: antiretroviral therapy prevents HIV transmission. Paper presented at: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2015; Vancouver, Canada. Abstract: MOAC0101LB.
3. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281-290.
4. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808-822.
5. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807.
6. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257-265.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed August 17, 2015.
8. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387-402.
9. World Health Organization. Guideline on When to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV. 2015. Available at: http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565-eng. pdf?ua=1. Accessed October 6, 2015.
10. Uy J, Armon C, Buchacz K, et al. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr. 2009;51:450-453.
11. Lima VD, Reuter A, Harrigan PR, et al. Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. AIDS. 2015;29:1871-1882.
12. Lodi S, Phillips A, Fidler S, et al. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. PLoS One. 2013;8:e75608.
13. Fogel JM, Wang L, Parsons TL, et al. Undisclosed antiretroviral drug use in a multi-national clinical trial (HPTN 052). J Infect Dis. 2013;208: 1624-1628.
14. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608-1618.
15. Hollinger FB, Bremer JW, Myers LE, et al. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol. 1992;30:1787-1794.
16. United Kingdom National External Quality Assessment Service (UK NEQAS). Available at: http://www.ukneqas.org.uk. Accessed September 12, 2015.
17. Hoen B, Bonnet F, Delaugerre C, et al. French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc. 2014; 17:19034.
18. World Health Organization. Maximizing the Treatment and Prevention Potential of Antiretroviral Drugs: Early Country Experiences towards Implementing a Treat-all Policy. 2015. Available at: http://apps.who.int/ iris/bitstream/10665/183599/1/WHO-HIV-2015.35-eng.pdf. Accessed September 12, 2015.
19. Kantor R, Smeaton L, Vardhanabhuti S, et al. Pretreatment HIV drug resistance and HIV-1 Subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis. 2015;60: 1541-1549.
20. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub- Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54:1660-1669.
21. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-1597.
22. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296:769-781.
23. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drugresistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.